NEUP — NEUPHORIA THERAPEUTICS INC
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
截至Q3 2026,共 13 家机构在其最新 13F 申报中持有 NEUP(NEUPHORIA THERAPEUTICS INC),合计申报市值 $2.75M,对应 773.35K 股。按股数计算较上季度增持 5.0%(+36.68K 股),申报市值环比下降 14.5%。持仓集中度较高:前五大持有人占申报市值的 90.6%,前十大的集中度为 100.0%。
与上一季度相比,2 家新建仓位、3 家加仓、2 家减仓、12 家清仓退出。13F 数据为季末快照,以上变动反映的是 Q3 2026 末的持仓状态,并非实时交易。
NEUPHORIA THERAPEUTICS INC(NEUP)的主要机构持有人包括 Lynx1 Capital Management LP、AdvisorShares Investments LLC、Balyasny Asset Management,按 13F 申报市值在本页 37 家持有人中排名居前。
NEUP 属于Health Care板块。
本页所有数据均来自美国证监会(SEC)13F 季度申报。13F 申报人需在季度结束后 45 天内披露 10 万美元以上的多头持仓;空头、期权对冲与季度内交易不在其列,因此这些数字反映的是机构持仓的季度快照,而非实时仓位。
机构逐季持仓趋势
| 季度 | 持有机构数 | 股数 | 金额 | 环比净变动 |
|---|---|---|---|---|
| Q3 2026 | 13 | 773.35K | $2.75M | +5.0% |
| Q2 2026 | 23 | 2.04M | $8.93M | +9.8% |
| Q1 2026 | 18 | 1.66M | $6.75M | +2.9% |
| Q4 2025 | 21 | 1.47M | $5.69M | +80.6% |
| Q3 2025 | 15 | 183.84K | $2.17M | -11.8% |
| Q2 2025 | 8 | 148.21K | $1.05M | -1.7% |
| Q1 2025 | 6 | 135.91K | $778.68K | -1.2% |
| Q4 2024 | 7 | 79.72K | $273.44K | — |
表内 8 个季度中,机构持股合计增加 870%(Q4 2024 → Q3 2026);单季变动最大的是 Q4 2025(+80.6%)。
前 25 大机构持仓人(Q3 2026) — 13 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 312.89K | $1.11M | 0.14% | 增持 | |
| 173.49K | $617.62K | 0.00% | 持有 | |
| 130.02K | $462.88K | 0.06% | 减持 | |
| 50.64K | $180.26K | 0.00% | 增持 | |
| 33.81K | $120.35K | 0.00% | 持有 | |
| 30.00K | $106.80K | 0.01% | 持有 | |
| 18.17K | $64.69K | 0.00% | 增持 | |
| 14.00K | $49.84K | 0.00% | 持有 | |
| 10.03K | $35.70K | 0.00% | 持有 | |
| 224 | $797 | 0.00% | 减持 | |
| 58 | $207 | 0.00% | 持有 | |
| 16 | $57 | 0.00% | 新进 | |
| 3 | $11 | 0.00% | 新进 |
更早季度的机构持仓记录(逐季列表): 返回前 25 大机构持仓人
Q2 2026 — 23 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 875.33K | $3.83M | 0.44% | 持有 | |
| 252.91K | $1.11M | 0.13% | 增持 | |
| 173.49K | $758.14K | 0.00% | 新进 | |
| 155.82K | $680.94K | 0.09% | 增持 | |
| 142.23K | $621.54K | 0.00% | 持有 | |
| 72.56K | $317.08K | 0.00% | 增持 | |
| 49.52K | $216.38K | 0.00% | 新进 | |
| 49.52K | $216.38K | 0.00% | 减持 | |
| 47.44K | $207.33K | 0.03% | 持有 | |
| 33.81K | $147.73K | 0.00% | 增持 | |
| 30.00K | $131.10K | 0.01% | 持有 | |
| 26.50K | $115.00K | 0.05% | 持有 | |
| 25.50K | $111.44K | 0.00% | 新进 | |
| 23.09K | $100.90K | 0.00% | 新进 | |
| 22.86K | $99.00K | 0.00% | 新进 | |
| 14.90K | $65.13K | 0.00% | 新进 | |
| 14.00K | $61.18K | 0.00% | 持有 | |
| 11.22K | $49.04K | 0.00% | 持有 | |
| 10.61K | $46.37K | 0.00% | 新进 | |
| 10.03K | $43.82K | 0.01% | 持有 | |
| 2.12K | $9.25K | 0.00% | 减持 | |
| 58 | $254 | 0.00% | 持有 | |
| 3 | $13 | 0.00% | 新进 |
Q1 2026 — 18 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 875.33K | $3.56M | 0.56% | 持有 | |
| 155.37K | $632.34K | 0.12% | 增持 | |
| 151.01K | $614.61K | 0.10% | 减持 | |
| 142.18K | $578.68K | 0.00% | 新进 | |
| 76.73K | $312.28K | 0.13% | 新进 | |
| 52.01K | $211.67K | 0.00% | 增持 | |
| 47.44K | $193.09K | 0.02% | 持有 | |
| 33.59K | $136.71K | 0.00% | 新进 | |
| 30.00K | $122.10K | 0.01% | 持有 | |
| 26.50K | $107.00K | 0.06% | 持有 | |
| 19.33K | $78.68K | 0.00% | 新进 | |
| 14.00K | $56.98K | 0.00% | 持有 | |
| 12.03K | $49.00K | 0.00% | 新进 | |
| 11.22K | $45.67K | 0.00% | 持有 | |
| 10.03K | $40.81K | 0.01% | 持有 | |
| 2.32K | $9.43K | 0.00% | 增持 | |
| 202 | $822 | 0.00% | 持有 | |
| 58 | $236 | 0.00% | 持有 |
Q4 2025 — 21 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 875.23K | $3.40M | 0.69% | 新进 | |
| 169.06K | $655.95K | 0.10% | 新进 | |
| 134.19K | $520.67K | 0.09% | 增持 | |
| 50.00K | $194.00K | 0.05% | 增持 | |
| 47.44K | $184.08K | 0.02% | 新进 | |
| 30.00K | $116.40K | 0.01% | 新进 | |
| 26.50K | $102.00K | 0.04% | 新进 | |
| 20.95K | $81.29K | 0.00% | 持有 | |
| 17.30K | $67.14K | 0.00% | 增持 | |
| 16.60K | $64.40K | 0.00% | 增持 | |
| 14.75K | $57.23K | 0.00% | 新进 | |
| 14.00K | $54.32K | 0.00% | 新进 | |
| 13.40K | $52.00K | 0.03% | 增持 | |
| 12.01K | $46.59K | 0.00% | 新进 | |
| 11.21K | $43.48K | 0.00% | 新进 | |
| 10.03K | $38.91K | 0.01% | 持有 | |
| 1.65K | $6.41K | 0.00% | 减持 | |
| 1.40K | $5.43K | 0.00% | 增持 | |
| 202 | $783 | 0.00% | 增持 | |
| 58 | $225 | 0.00% | 增持 | |
| 18 | $70 | 0.00% | 增持 |
Q3 2025 — 15 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 58.56K | $690.46K | 0.11% | 减持 | |
| 21.45K | $252.92K | 0.09% | 新进 | |
| 20.95K | $247.00K | 0.00% | 新进 | |
| 18.33K | $216.10K | 0.00% | 新进 | |
| 18.33K | $216.10K | 0.00% | 新进 | |
| 15.67K | $184.74K | 0.00% | 新进 | |
| 12.98K | $153.01K | 0.00% | 新进 | |
| 10.03K | $118.22K | 0.05% | 持有 | |
| 4.91K | $57.87K | 0.04% | 新进 | |
| 2.17K | $25.56K | 0.00% | 新进 | |
| 410 | $4.83K | 0.00% | 新进 | |
| 33 | $389 | 0.00% | 持有 | |
| 17 | $201 | 0.00% | 增持 | |
| 7 | $83 | 0.00% | 持有 | |
| 2 | $24 | 0.00% | 新进 |
Q2 2025 — 8 家基金
| 基金 | 股数 | 金额 | 组合权重 | 变化 |
|---|---|---|---|---|
| 67.73K | $480.90K | 0.09% | 减持 | |
| 45.81K | $325.22K | 0.09% | 持有 | |
| 14.61K | $103.70K | 0.00% | 新进 | |
| 10.03K | $71.19K | 0.03% | 持有 | |
| 10.00K | $71.00K | 0.00% | 持有 | |
| 33 | $234 | 0.00% | 减持 | |
| 7 | $50 | 0.00% | 持有 | |
| 1 | $7 | 0.00% | 新进 |
新建仓(Q3 2026)
- Fidelity Management & Research (FMR) 16 股 · $57
- BARCLAYS PLC 3 股 · $11
完全清仓(较上季)
- Lynx1 Capital Management LP 卖出 875.33K 股 · $3.83M
- Balyasny Asset Management 卖出 142.23K 股 · $621.54K
- Citadel Advisors 卖出 72.56K 股 · $317.08K
- GEODE CAPITAL MANAGEMENT, LLC 卖出 49.52K 股 · $216.38K
- Ikarian Capital, LLC 卖出 47.44K 股 · $207.33K
- FNY Investment Advisers, LLC 卖出 26.50K 股 · $115.00K
- Renaissance Technologies 卖出 25.50K 股 · $111.44K
- XTX Topco Ltd 卖出 23.09K 股 · $100.90K
- HRT FINANCIAL LP 卖出 22.86K 股 · $99.00K
- COMMONWEALTH EQUITY SERVICES, LLC 卖出 11.22K 股 · $49.04K
- Northern Trust Corp 卖出 10.61K 股 · $46.37K
- Caitong International Asset Management Co., Ltd 卖出 3 股 · $13
基金持仓历史 — 各季度股数(前 20 只基金)
| 基金 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 312.89K | 252.91K | 155.37K | 134.19K | 58.56K | 67.73K | 69.66K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 173.49K | 173.49K | — | — | — | — | — | — |
| Shay Capital LLC | 130.02K | 155.82K | 151.01K | 169.06K | — | — | — | — |
| Geode Capital Management | 50.64K | 49.52K | 52.01K | 17.30K | 12.98K | — | — | — |
| VANGUARD FIDUCIARY TRUST CO | 33.81K | 33.81K | 33.59K | — | — | — | — | — |
| ADAR1 Capital Management, LLC | 30.00K | 30.00K | 30.00K | 30.00K | — | — | — | — |
| JANE STREET GROUP, LLC | 18.17K | 14.90K | — | 16.60K | 15.67K | — | — | 13.31K |
| BOOTHBAY FUND MANAGEMENT, LLC | 14.00K | 14.00K | 14.00K | 14.00K | — | — | — | — |
| Merck & Co., Inc. | 10.03K | 10.03K | 10.03K | 10.03K | 10.03K | 10.03K | 10.03K | 10.03K |
| UBS Group AG | 224 | 2.12K | 2.32K | 1.65K | 2.17K | — | — | 2.98K |
| Morgan Stanley | 58 | 58 | 58 | 58 | 7 | 7 | 7 | 7 |
| Fidelity Management & Research (FMR) | 16 | — | — | — | 2 | — | — | — |
| BARCLAYS PLC | 3 | — | — | — | — | — | — | — |
| Lynx1 Capital Management LP | — | 875.33K | 875.33K | 875.23K | — | 45.81K | 45.81K | 45.81K |
| Balyasny Asset Management | — | 142.23K | 142.18K | — | — | — | — | — |
| Citadel Advisors | — | 72.56K | 19.33K | — | — | 14.61K | — | — |
| Squadron Capital Management LLC | — | — | 76.73K | — | — | — | — | — |
| DIADEMA PARTNERS LP | — | — | — | 50.00K | 21.45K | — | — | — |
| Vanguard Group | — | — | — | 20.95K | 20.95K | — | — | — |
| GEODE CAPITAL MANAGEMENT, LLC | — | 49.52K | — | — | — | — | — | — |
▲ 低买(基金新建/增持,下一季股价上涨 ≥5%) ▼ 高卖(基金减持,下一季股价下跌 ≥5%)
拖拽/滚轮缩放 · 默认显示最近一年 · 标注来自 13F 申报中的季度基金操作 · 悬停查看详情
常见问题
Which funds hold NEUP?
As of 2026-Q3, 13 institutional funds reported holding NEUP (NEUPHORIA THERAPEUTICS INC) in SEC 13F filings, with a combined reported value of $2.75M.
How many shares of NEUP do institutions own?
13F filers reported 773.35K shares of NEUP, worth $2.75M in aggregate at the end of 2026-Q3.
Is institutional ownership of NEUP rising or falling?
Share counts moved +5.0% versus the prior quarter — accumulation.
Who are the top institutional holders of NEUP?
The largest 13F holders are Lynx1 Capital Management LP, AdvisorShares Investments LLC, Balyasny Asset Management, VANGUARD CAPITAL MANAGEMENT LLC, Shay Capital LLC; the top 25 are ranked at the top of this page.
Who are the major shareholders of NEUPHORIA THERAPEUTICS INC?
The major shareholders of NEUPHORIA THERAPEUTICS INC (NEUP) by reported 13F value are Lynx1 Capital Management LP, AdvisorShares Investments LLC, Balyasny Asset Management, VANGUARD CAPITAL MANAGEMENT LLC, Shay Capital LLC, among 37 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.